Crocodile Peptide Market

Crocodile Peptide Market Outlook (2022-2032)

The crocodile peptide market is presently at the nascent stage and consists of several competitors who are working on getting the crocodile peptide approved by the FDA (Food and Drug Administration). Research into crocodiles' antibiotics and other medicinal properties is not recent, but given the growth of drug-tolerant bacteria and viruses and the declining effectiveness, the work on crocodile peptides appears to be gaining some traction.

As per a World Health Organisation survey in 2022, The cancer is leading cause of death across the globe owing to nearly 10 Million deaths in 2020. The available medications in the treatment of cancer are often regarded to have side effects and these may become less effective. Owing to this factor there is a rise in research in peptide markets.

Biologists studying crocodile activity found that while crocodiles often participate in aggressive territorial actions and dangerous interactions with other species, very few have ever developed serious infections from their injuries. Scientists have started synthesizing the chemical structure of the reptile peptide because of the positive results of these experiments.

What are the factors that impels the use of the animal peptide industry?

Until feeding, chemical, enzymatic, hydrolysis or microbial protein in animal by-products or plant-source feed is an effective means of producing high-quality small or large peptides for both nutritional and physiological or regulatory roles.

It is expected that rising health-conscious consumers across the globe coupled with raising awareness about the health benefits of protein would promote market development. Consumption of bioactive peptides and protein products has been shown to have multiple health benefits as they have many physiological functionalities such as strengthening the digestive, nervous, and cardiovascular systems.

Reptiles tend to have an ancient innate immune system which has attracted scientists to identify novel uses for peptides. The improvement in biochemistry and genomic science research has driven the growth in this sector. The companies are heavily investing in bioinformatics analysis that is likely to reveal novel analysis in the mammal immune systems which is propelling the interest of medical companies in this sector.

One substance, named crocodilian, in particular, has proven to be interesting. But there is absolutely no proof that this could be used as a drug. The high initial investment and manufacturing cost of peptides needed in the early research phase is a major challenge for crocodile peptide research and development. Lack of financial support for the biotechnology and pharmaceutical industries in research or peptide therapy is hindering the global expansion of the crocodile peptide market.

What are the restraints faced by the industry?

Animal peptides are traditionally regarded as ineffective drug candidates as it doesn’t not favors characteristics determining pharmacokinetic behavior. The uncertainty in plasma stability and circulation of half-life is likely to act as limiting the penetration of peptide-based drugs in the forecast period. Lower yields of some peptides cause issues of insolubility. The initial peptide synthesis is often affected by the aggregation state of ribosomes and modulation. The vendors involved in peptide manufacturing find it a very long procedure and considered it kinetically unfavorable.

Segment Wise Insights

On the basis of the type of peptide, the industry is divided into cationic, anionic, and linear cationic. These peptides are rich in amino acids and possess cysteine made of disulfide bonds. These are rich in aspartic acids and have a high amount of glutamic.

These are dominantly used in cosmetics owing to a higher amount of glycerine content in the peptide. Cationic peptides are a good source for the production of conventional antibiotics therapies. Cecropins is having a host defense system that proves to be effective in treating bacterial infection. Owing to these benefits the segment is likely to record the fastest CAGR in the forecast period.

“Peptide effective in treating bacterial infections and used as vaccine”

Based on the industry the pharmaceuticals segment is reigning the market share owing to awareness about the medical benefits of peptides in medicines. The peptide drugs are effective as antibacterial in treating infections caused by bacteria in mammals.

Peptide vaccines are set to replace conventional vaccines and are being used to treat malignant viruses such as Mouth and Foot disease. The peptide has gained attention for medical properties such as in animal reproduction and diabetes diagnosis. The faster metabolism of peptide-based medicines is another factor that likely to give traction to this market owing to the reduced risk of possible livestock contamination.

Regional Outlook

The increase in research is the main driving force of North America's market for crocodile peptides. Asia Pacific is the most developed field in the antibacterial peptide market for animals. The increase in animal healthcare spending is a key factor responsible for market growth.

During the forecast period, the increasing resistance to conventional antibiotics is likely to be the key driver of the market for animal antibacterial peptides including crocodile peptides. In addition, the rise in the use of antibiotics in animal feed for the treatment of various infections and diseases is expected to drive the growth of the crocodile peptide market during the forecast period.

Competitive Landscape

According to crocodile researcher Grahame Webb, it has been confirmed that major pharmaceutical companies in America are now working hard to produce crocodile peptides using crocodile blood and oils, although it is hard to justify which companies are working on crocodile peptides for commercial reasons. Leading industry players are working to conduct anti-microbial peptide work.

Symcel and Colzyx, for example, have worked together to study antimicrobial peptides and their ability to curb bacterial production. Newly founded companies such as Nuritas combine artificial intelligence and DNA analysis to identify animal peptides that can support a health-related cause.

Recent development

• In 2018, Symcel a leading pharmaceutical technology firm announced a partnership with the Karolinska Institute for validating susceptibility testing in the clinical antimicrobial calScreener. This collaboration is intended to evaluate the effectiveness of calScreener which is designed for understanding cell metabolism in real time.

Segmentation

• By Peptide Type:

  • Anionic Peptides
  • Cationic Peptides
  • Linear Cationic

• By Synthesis:

  • Solid Phase
  • Liquid Phase
  • Hybrid Phase

• By End-Use:

  • Pharmaceutical & Biotechnology Companies
  • Contract Development Organizations (CRO)
  • Academic and Research Institutes

• By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Middle East & Africa